SLC6A3 and Parkinson disease: The results show that ADLL therapy has effects on three outcome parameters in the 2 iRBD patients: it markedly improves the severity of the RBD phenotype (reduction of aggressive dream content and dream enactment), reverses the loss of striatal dopamine-transporter binding in the nigrostriatal system, and stabilizes the PD-typical pathological metabolic brain pattern.